FDA advisers narrowly back accelerated approval of Sarepta gene therapy

U.S. Food and Drug Administration advisers voted 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.’s gene therapy for Duchenne muscular dystrophy despite questions about its clinical benefit and safety.

Should it be approved, the first-of-its-kind potential one-time experimental therapy, called SRP-9001, could radically change how patients with DMD are treated. Earlier this week, the FDA said Sarepta did not offer “unambiguous evidence” the therapy will benefit patients with the deadly muscle-wasting disease.

Sarepta
SRPT,
-0.88%,
which hopes to gain fast-track approval via the FDA based on limited current data, is conducting a late-stage trial to confirm the therapy’s benefits to patients. The first batch of data from the trial is expected by December; full results should be available in early 2024.

The FDA is expected to make a decision by May 29. The agency usually mirrors the  advice of its advisers, though it is not obligated.

“Today’s advisory committee outcome is extremely important to the patient community, who are in urgent need of new therapies,” said Sarepta Chief Executive Doug Ingram said in a statement late Friday. “With the May 29 action date our top priority, we will work collaboratively with the FDA to complete the review of our BLA for SRP 9001.”

You May Also Like

Erdoğan signals economic shift for Turkey as he revamps cabinet

Turkish president Recep Tayyip Erdoğan signalled a move to more orthodox economic…

Deutsche banker takes over asset manager in the eye of an ESG storm

Stefan Hoops had known for some time that he was in the…

Wael Sawan, Shell lifer taking helm to steer through energy transition

When Wael Sawan takes the helm at Shell in January, the new…

German consumer sentiment expected to drop to new record low in July

Consumer confidence in Germany is set to fall in July to an…